Cargando…
Transformative Concepts for Drug Design: Target Wrapping
In spite of the enticing promises of the post-genomic era, the pharmaceutical world is in a state of disarray. Drug discovery seems now riskier and more uncertain than ever. Thus, projects get routinely terminated in mid-stage clinical trials, new targets are getting harder to find, and successful t...
| Clasificación: | Libro Electrónico |
|---|---|
| Autor principal: | |
| Autor Corporativo: | |
| Formato: | Electrónico eBook |
| Idioma: | Inglés |
| Publicado: |
Berlin, Heidelberg :
Springer Berlin Heidelberg : Imprint: Springer,
2010.
|
| Edición: | 1st ed. 2010. |
| Temas: | |
| Acceso en línea: | Texto Completo |
MARC
| LEADER | 00000nam a22000005i 4500 | ||
|---|---|---|---|
| 001 | 978-3-642-11792-3 | ||
| 003 | DE-He213 | ||
| 005 | 20220114122231.0 | ||
| 007 | cr nn 008mamaa | ||
| 008 | 100427s2010 gw | s |||| 0|eng d | ||
| 020 | |a 9783642117923 |9 978-3-642-11792-3 | ||
| 024 | 7 | |a 10.1007/978-3-642-11792-3 |2 doi | |
| 050 | 4 | |a R856-857 | |
| 072 | 7 | |a MQW |2 bicssc | |
| 072 | 7 | |a TEC059000 |2 bisacsh | |
| 072 | 7 | |a MQW |2 thema | |
| 082 | 0 | 4 | |a 610.28 |2 23 |
| 100 | 1 | |a Fernandez, Ariel. |e author. |4 aut |4 http://id.loc.gov/vocabulary/relators/aut | |
| 245 | 1 | 0 | |a Transformative Concepts for Drug Design: Target Wrapping |h [electronic resource] / |c by Ariel Fernandez. |
| 250 | |a 1st ed. 2010. | ||
| 264 | 1 | |a Berlin, Heidelberg : |b Springer Berlin Heidelberg : |b Imprint: Springer, |c 2010. | |
| 300 | |a X, 230 p. |b online resource. | ||
| 336 | |a text |b txt |2 rdacontent | ||
| 337 | |a computer |b c |2 rdamedia | ||
| 338 | |a online resource |b cr |2 rdacarrier | ||
| 347 | |a text file |b PDF |2 rda | ||
| 505 | 0 | |a Protein Cooperativity and Wrapping: Two Themes in the Transformative Platform of Molecular Targeted Therapy -- Wrapping Defects and the Architecture of Soluble Proteins -- Folding Cooperativity and the Wrapping of Intermediate States of Soluble Natural Proteins -- Wrapping Deficiencies and De-wetting Patterns in Soluble Proteins: A Blueprint for Drug Design -- Under-Wrapped Proteins in the Order-Disorder Twilight: Unraveling the Molecular Etiology of Aberrant Aggregation -- Evolution of Protein Wrapping and Implications for the Drug Designer -- Wrapping as a Selectivity Filter for Molecular Targeted Therapy: Preliminary Evidence -- Re-engineering an Anticancer Drug to Make It Safer: Modifying Imatinib to Curb Its Side Effects -- Wrapping Patterns as Universal Markers for Specificity in the Therapeutic Interference with Signaling Pathways -- Fulfilling a Therapeutic Imperative in Cancer Treatment: Control of Multi-target Drug Impact -- Inducing Folding By Crating the Target -- Wrapper Drugs as Therapeutic Editors of Side Effects -- Wrapper Drugs for Personalized Medicine -- Last Frontier and Back to the Drawing Board: Protein-Water Interfacial Tension in Drug Design. | |
| 520 | |a In spite of the enticing promises of the post-genomic era, the pharmaceutical world is in a state of disarray. Drug discovery seems now riskier and more uncertain than ever. Thus, projects get routinely terminated in mid-stage clinical trials, new targets are getting harder to find, and successful therapeutic agents are often recalled as unanticipated side effects are discovered. Exploiting the huge output of genomic studies to make safer drugs has proven to be much more difficult than anticipated. More than ever, the lead in the pharmaceutical industry depends on the ability to harness innovative research, and this type of innovation can only come from one source: fundamental knowledge. This book squarely addresses this crucial problem since it introduces fundamental discoveries in basic biomolecular research that hold potential to broaden the technological base of the pharmaceutical industry. The book takes a fresh and fundamental look at the problem of how to design an effective drug with controlled specificity. Since the novel transformative concepts are unfamiliar to most practitioners, the first part of this book explains matters very carefully starting from a fairly elementary physico-chemical level. The second part of the book is devoted to practical applications, aiming at nothing less than a paradigm shift in drug design. This book is addressed to scientists working at the cutting edge of research in the pharmaceutical industry, but the material is at the same time accessible to senior undergraduates or graduate students interested in drug discovery and molecular design. | ||
| 650 | 0 | |a Biomedical engineering. | |
| 650 | 0 | |a Medicinal chemistry. | |
| 650 | 0 | |a Biophysics. | |
| 650 | 0 | |a Cancer. | |
| 650 | 1 | 4 | |a Biomedical Engineering and Bioengineering. |
| 650 | 2 | 4 | |a Medicinal Chemistry. |
| 650 | 2 | 4 | |a Biophysics. |
| 650 | 2 | 4 | |a Cancer Biology. |
| 710 | 2 | |a SpringerLink (Online service) | |
| 773 | 0 | |t Springer Nature eBook | |
| 776 | 0 | 8 | |i Printed edition: |z 9783642117930 |
| 776 | 0 | 8 | |i Printed edition: |z 9783642424588 |
| 776 | 0 | 8 | |i Printed edition: |z 9783642117916 |
| 856 | 4 | 0 | |u https://doi.uam.elogim.com/10.1007/978-3-642-11792-3 |z Texto Completo |
| 912 | |a ZDB-2-ENG | ||
| 912 | |a ZDB-2-SXE | ||
| 950 | |a Engineering (SpringerNature-11647) | ||
| 950 | |a Engineering (R0) (SpringerNature-43712) | ||